The problem with drawing conclusions from the analysis is that...

The problem with drawing conclusions from the analysis is that in December 2010 and March 2011 DS would have been selling Inavir to distributors to build stocks of the drug. Tamiflu and Relenza do not need to do this because they have been around for a while and distributors already have stocks. That means Inavir sales were inflated relative to Relenza and Tamiflu during those periods. But I dont think this was an issue in March 2012 quarter